Suppr超能文献

组织学不良的播散性非霍奇金淋巴瘤的治疗

The treatment of disseminated non-Hodgkin's lymphoma of unfavourable histology.

作者信息

Gallagher C J, Copplestone A, Meikle J D, Lister T A

出版信息

Cancer Chemother Pharmacol. 1982;8(2):237-41. doi: 10.1007/BF00255490.

Abstract

Forty-eight consecutive previously untreated adults with advanced non-Hodgkin's lymphoma (NHL) of unfavourable histological type were referred to the Department of medical Oncology at St. Bartholomew's Hospital, london, between 1972 and 1977. They received adriamycin, vincristine, prednisolone and L-asparaginase (OPAL) initially, and those in whom complete remission was achieved proceeded to cranial irradiation and intrathecal methotrexate, followed by continuous oral maintenance chemotherapy comprising weekly methotrexate, cyclophosphamide, and daily 6-mercaptopurine for 3 years. Complete remission was achieved in 24 of the 48 (50%). The median duration of remission was 10 months, none patients continuing without relapse for between 3 and 7 years. The median survival was 9 months, 12 patients being alive and disease-free (three in second remission) after between 3 1/2 and 8 1/2 years. The prognosis was significantly better in patients with nodal stages II and III (disease) than in those with stage IV, for both response (P = less than 0.05) and survival (P = 0.002). Patients in whom complete remission was achieved survived significantly longer than those in whom it was not, regardless of stage. These results confirm our preliminary observations with this treatment programme that a proportion of patients with stage II and II unfavourable histology NHL may be curable although the outlook for stage IV remains poor.

摘要

1972年至1977年间,48例组织学类型不佳的晚期非霍奇金淋巴瘤(NHL)初治成年患者被转诊至伦敦圣巴塞洛缪医院医学肿瘤科。他们最初接受阿霉素、长春新碱、泼尼松龙和L-天冬酰胺酶(OPAL)治疗,那些达到完全缓解的患者接着接受颅脑照射和鞘内注射甲氨蝶呤,随后进行持续口服维持化疗,包括每周一次甲氨蝶呤、环磷酰胺以及每日一次6-巯基嘌呤,持续3年。48例患者中有24例(50%)达到完全缓解。缓解期的中位数为10个月,没有患者持续3至7年无复发。中位生存期为9个月,12例患者在3.5至8.5年后仍存活且无疾病(3例处于第二次缓解期)。对于缓解情况(P<0.05)和生存期(P = 0.002),II期和III期(疾病)患者的预后明显优于IV期患者。无论处于何期,达到完全缓解的患者比未达到完全缓解的患者存活时间显著更长。这些结果证实了我们对该治疗方案的初步观察,即部分II期和III期组织学类型不佳的NHL患者可能治愈,尽管IV期患者的前景仍然不佳。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验